These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 17878957)

  • 21. Dicarboxylic acid azacycle l-prolyl-pyrrolidine amides as prolyl oligopeptidase inhibitors and three-dimensional quantitative structure-activity relationship of the enzyme-inhibitor interactions.
    Jarho EM; Wallén EA; Christiaans JA; Forsberg MM; Venäläinen JI; Männistö PT; Gynther J; Poso A
    J Med Chem; 2005 Jul; 48(15):4772-82. PubMed ID: 16033257
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multiple central nervous system targets for eliciting beneficial effects on memory and cognition.
    Buccafusco JJ; Terry AV
    J Pharmacol Exp Ther; 2000 Nov; 295(2):438-46. PubMed ID: 11046074
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Spatial association of prolyl oligopeptidase, inositol 1,4,5-triphosphate type 1 receptor, substance P and its neurokinin-1 receptor in the rat brain: an immunohistochemical colocalization study.
    Myöhänen TT; Venäläinen JI; Garcia-Horsman JA; Männistö PT
    Neuroscience; 2008 Jun; 153(4):1177-89. PubMed ID: 18455882
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Subchronic administration of rosmarinic acid, a natural prolyl oligopeptidase inhibitor, enhances cognitive performances.
    Park DH; Park SJ; Kim JM; Jung WY; Ryu JH
    Fitoterapia; 2010 Sep; 81(6):644-8. PubMed ID: 20230877
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An introduction of a pyridine group into the structure of prolyl oligopeptidase inhibitors.
    Jarho EM; Venäläinen JI; Juntunen J; Yli-Kokko AL; Vepsäläinen J; Christiaans JA; Forsberg MM; Järvinen T; Männistö PT; Wallén EA
    Bioorg Med Chem Lett; 2006 Nov; 16(21):5590-3. PubMed ID: 16919454
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Localization of prolyl oligopeptidase in the thalamic and cortical projection neurons: a retrograde neurotracing study in the rat brain.
    Myöhänen TT; Kääriäinen TM; Jalkanen AJ; Piltonen M; Männistö PT
    Neurosci Lett; 2009 Jan; 450(2):201-5. PubMed ID: 19041368
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Suggested functions for prolyl oligopeptidase: a puzzling paradox.
    Brandt I; Scharpé S; Lambeir AM
    Clin Chim Acta; 2007 Feb; 377(1-2):50-61. PubMed ID: 17034776
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The angiotensin AT4 receptor subtype as a target for the treatment of memory dysfunction associated with Alzheimer's disease.
    Wright JW; Harding JW
    J Renin Angiotensin Aldosterone Syst; 2008 Dec; 9(4):226-37. PubMed ID: 19126664
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The serotonin 5-HT6 receptor: a viable drug target for treating cognitive deficits in Alzheimer's disease.
    Geldenhuys WJ; Van der Schyf CJ
    Expert Rev Neurother; 2009 Jul; 9(7):1073-85. PubMed ID: 19589055
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The natural product berberine is a human prolyl oligopeptidase inhibitor.
    Tarrago T; Kichik N; Seguí J; Giralt E
    ChemMedChem; 2007 Mar; 2(3):354-9. PubMed ID: 17295371
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The neuroprotective effects of GLP-1: possible treatments for cognitive deficits in individuals with mood disorders.
    McIntyre RS; Powell AM; Kaidanovich-Beilin O; Soczynska JK; Alsuwaidan M; Woldeyohannes HO; Kim AS; Gallaugher LA
    Behav Brain Res; 2013 Jan; 237():164-71. PubMed ID: 23000536
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Issues about the physiological functions of prolyl oligopeptidase based on its discordant spatial association with substrates and inconsistencies among mRNA, protein levels, and enzymatic activity.
    Myöhänen TT; García-Horsman JA; Tenorio-Laranga J; Männistö PT
    J Histochem Cytochem; 2009 Sep; 57(9):831-48. PubMed ID: 19687473
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pyrrolidinyl pyridone and pyrazinone analogues as potent inhibitors of prolyl oligopeptidase (POP).
    Haffner CD; Diaz CJ; Miller AB; Reid RA; Madauss KP; Hassell A; Hanlon MH; Porter DJ; Becherer JD; Carter LH
    Bioorg Med Chem Lett; 2008 Aug; 18(15):4360-3. PubMed ID: 18606544
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular dynamics study of prolyl oligopeptidase with inhibitor in binding cavity.
    Kaszuba K; Rog T; St Pierre JF; Mannisto PT; Karttunen M; Bunker A
    SAR QSAR Environ Res; 2009 Oct; 20(7-8):595-609. PubMed ID: 20024801
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeted Covalent Inhibition of Prolyl Oligopeptidase (POP): Discovery of Sulfonylfluoride Peptidomimetics.
    Guardiola S; Prades R; Mendieta L; Brouwer AJ; Streefkerk J; Nevola L; Tarragó T; Liskamp RMJ; Giralt E
    Cell Chem Biol; 2018 Aug; 25(8):1031-1037.e4. PubMed ID: 29779956
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study.
    Hampel H; Ewers M; Bürger K; Annas P; Mörtberg A; Bogstedt A; Frölich L; Schröder J; Schönknecht P; Riepe MW; Kraft I; Gasser T; Leyhe T; Möller HJ; Kurz A; Basun H
    J Clin Psychiatry; 2009 Jun; 70(6):922-31. PubMed ID: 19573486
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Deficient activity of mammalian prolyl oligopeptidase on the immunoactive peptide digestion in coeliac disease.
    Garcia-Horsman JA; Venäläinen JI; Lohi O; Auriola IS; Korponay-Szabo IR; Kaukinen K; Mäki M; Männistö PT
    Scand J Gastroenterol; 2007 May; 42(5):562-71. PubMed ID: 17454876
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Flavonoids with prolyl oligopeptidase inhibitory activity isolated from Scutellaria racemosa Pers.
    Marques MR; Stüker C; Kichik N; Tarragó T; Giralt E; Morel AF; Dalcol II
    Fitoterapia; 2010 Sep; 81(6):552-6. PubMed ID: 20117183
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting the insulin-regulated aminopeptidase/AT4 receptor for cognitive disorders.
    Hallberg M
    Drug News Perspect; 2009 Apr; 22(3):133-9. PubMed ID: 19440555
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Animal models of cognitive dysfunction.
    Tayebati SK
    Mech Ageing Dev; 2006 Feb; 127(2):100-8. PubMed ID: 16293295
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.